38 studies on Amylin agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Phase 1 trial to compare Cagrilintide B (with placebo semaglutide I) and Cagrilintide D blood levels in 234 adults with overweight or obesity over 17 weeks.
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefi…
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because…
The successful completion of enrollment for this Phase 3 trial is a crucial step towards potentially offering a highly effective new treatment option for obesity. If the results demonstrate significant weight loss and…
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
The development of highly effective weight loss medications is crucial for addressing the global obesity epidemic, which contributes to numerous health complications. While individual GIP RAs and amylin agonists show …
The successful demonstration of comparability between different CagriSema delivery devices is a critical step for its future availability and patient accessibility. This Phase 3 study aims to ensure that regardless of…
If CagriSema proves effective, it could represent a significant advancement in managing Chronic Kidney Disease in patients with Type 2 Diabetes and obesity, a population with high unmet medical needs. The potential fo…
This summary highlights the continued global scientific focus on obesity as a multifaceted disease with profound implications for public health. The emphasis on novel therapeutic approaches presented at the WCIRDC sug…
Understanding how Cagrilintide is processed in individuals with hepatic impairment is a critical step in its development, as it directly informs safe and effective dosing strategies. This pharmacokinetic data will gui…
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
If successful, this Phase 3 trial could establish cagrilintide as a novel and effective treatment option for individuals struggling with overweight or obesity. The 64-week duration is designed to demonstrate sustained…
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
The initiation of this Phase 1 trial is a significant step in the development of new treatments for obesity and overweight, conditions with a substantial global health burden. If NNC0174-1213 demonstrates a favorable …
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.